Skip to main content
Caplight Logo









ImmunAbs Inc.

ImmunAbs Inc.

Private
SeoulHealthcare & Life Scienceshttp://immunabs.com/

Last Round

Grant

Jan 31, 2024

Total Funding Raised

$34.98M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ImmunAbs Inc. is a biotechnology company that develops novel antibody therapeutics for autoimmune diseases, diabetic retinopathy, and metabolic syndrome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

monoclonal antibodiesantibody discoverybiotech R&Ddrug developmenttherapeutic candidatesphage displaysingle B-cell cloningclinical-stage biotechdrug licensingbiotech platformdrug discoverywet-labbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunAbs Inc. Comparables

Compare ImmunAbs Inc. with similar companies based on industry and business-model similarity.

ImmunAbs Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbClon Inc.
78%
Hummingbird Bioscience
77%
Y-Biologics
76%

ImmunAbs Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 31, 2024
Series BNov 30, 2022
GrantNov 1, 2021
Series ASep 30, 2021

Key People

Founding team and executive leadership

Dongjo Kim

Chief Executive Officer

Executive Team

ImmunAbs Inc. Investors

Notable investors and investment history

ImmunAbs Inc. investors
InvestorRounds
D3 Jubilee PartnersSeries B
Seoul Investment PartnersSeries B, Series A
CKD Venture CapitalSeries B
Korea Drug Development FundGrant
Alpen RoutePre Seed
LogInvestmentPre Seed
DS Asset ManagementPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 482% MoM.

  • Nov 30, 2022

    $9.56M round with participation from CKD Venture Capital and Daekyo Investment.

ImmunAbs Inc. Filings

Explore SEC and related filing metadata, where available.

ImmunAbs Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ImmunAbs Inc.'s valuation, stock price, and market status.

Is ImmunAbs Inc. a public or private company?

ImmunAbs Inc. is a private company.

What is the current stock price of ImmunAbs Inc.?

ImmunAbs Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is ImmunAbs Inc. worth (valuation)?

Valuation information for ImmunAbs Inc. is not publicly available.

Can I buy ImmunAbs Inc. stock?

ImmunAbs Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ImmunAbs Inc.'s last funding round?

ImmunAbs Inc.'s most recent funding round was Grant on January 31, 2024.

Who are the main investors in ImmunAbs Inc.?

Key investors in ImmunAbs Inc. include D3 Jubilee Partners, Seoul Investment Partners, CKD Venture Capital, Korea Drug Development Fund, Hana Securities.

Will ImmunAbs Inc. IPO soon?

No public IPO plans have been announced for ImmunAbs Inc..

How can I track ImmunAbs Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImmunAbs Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range12
Year Founded2017
Last FundingJan 31, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?